Immunovant, Inc. IMVT announced top-line results from the initial cohort of patients in an ongoing 24-week phase II study of batoclimab in patients with Graves’ disease (GD), observing more than 50% ...
Results from oral glucose tolerance testing yield information that can be used to stratify women with varying levels of risk ...
Immunovant, Inc. IMVT shares gained 10.8% on Wednesday after the company announced new six-month off-treatment results from a proof-of-concept study evaluating its investigational candidate, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback